Back

Favorable effect of aficamten on left atrial mechanics in obstructive hypertrophic cardiomyopathy: insights from the SEQUOIA-HCM trial

9 May 2026 (15:47 - 15:55)
Organised by: Logo
Congress Presentation Part of: Advanced phenotyping and risk stratification in cardiomyopathies and myocarditis Hypertrophic Cardiomyopathy HFA Premium Access Heart Failure 2026 Heart Failure Association (HFA)

About the speaker

Photo
Doctor Yasuhiro Hamatani

Brigham and Women's Hospital, Harvard Medical School, Boston (United States of America)

6 More presentations in this session

Presentation thumbnail
Clinical presentation and prognostic impact of eosinophilic myocarditis associated to eosinophilic granulomatosis with polyangiitis
Doctor S. Ghidini (Milan, IT)
Abstract Slides Video
Presentation thumbnail
Native T1 for diagnosis and risk prediction in amyloid transthyretin cardiomyopathy
Doctor A. Aimo (Pisa, IT)
Abstract Slides Video
Presentation thumbnail
Early experience optimizing immunosuppressive use and monitoring in MyPEAK-1, a first-in-human study of TN-201, an AAV9 gene replacement therapy in MYBPC3-associated hypertrophic cardiomyopathy
Professor M. Desai (Cleveland, US)
Abstract Slides Video
Presentation thumbnail
Cardiac magnetic resonance-based phenotyping, genetic architecture, and outcomes in dilated and non-dilated left ventricular cardiomyopathy
Ms A. Heymans (Maastricht, NL)
Abstract Slides Video
Presentation thumbnail
Staging classification of transthyretin cardiac amyloidosis based on the extent of cardiac damage at echocardiography: a large multicentric Registry.
Doctor D. Tomasoni (Brescia, IT)
Abstract Slides Video

Access the full session

Session thumbnail
Advanced phenotyping and risk stratification in cardiomyopathies and myocarditis
Video

The Event

Event poster

Heart Failure 2026

9 May 2026 15:47 CET
You may be interested in
thumbnail
Congress Presentation
Serial changes in left atrial strain in symptomatic obstructive hypertrophic cardiomyopathy treated with mavacamten: insights from VALOR-HCM trial
thumbnail
Congress Session
Late breaking clinical trials: LVAD, HFpEF and hypertrophic cardiomyopathy
thumbnail
Congress Presentation
Impact of Aficamten on Echocardiographic Cardiac Structure and Function in Adults with Symptomatic Obstructive Hypertrophic Cardiomyopathy

ESC 365 is supported by

novartis Explore sponsored resources
novo-nordisk Explore sponsored resources

ESC 365 is supported by

novartis Explore sponsored resources
novo-nordisk Explore sponsored resources